容大感光(300576.SZ):主要產品包括PCB光刻膠、顯示用光刻膠、半導體用光刻膠等
格隆匯11月5日丨容大感光(300576.SZ)在投資者互動平台表示,公司主要產品包括PCB光 刻膠、顯示用光 刻膠、半導體用光 刻膠等。公司從創立開始就一直專注感光電子化學品的研發、生產和銷售,公司所推出的的產品面對的競爭幾乎都是國際上行業的巨頭,今天公司的市場份額是在與國際上行業巨頭激烈競爭下取得的。可以説,公司的發展史就是一部國產光 刻膠產品逐漸實現進口替代的歷史。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.